Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company that specializes in developing products for genetically defined diseases with high unmet medical needs, is making strides in the United States. The company's losmapimod, a small molecule for treating facioscapulohumeral muscular dystrophy, is currently undergoing phase III clinical trials. In addition, FTX-6058, an oral fetal hemoglobin inducer for sickle cell disease and other hemoglobinopathies, including beta-thalassemia, is undergoing phase I clinical trials. Fulcrum Therapeutics is also researching drug targets for rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. The company has several key collaborations with industry leaders, including Acceleron Pharma Inc. and MyoKardia, Inc., to target specific pathways associated with pulmonary diseases and develop novel therapies for genetic cardiomyopathies, respectively. Incorporated in 2015 and headquartered in Cambridge, Massachusetts, Fulcrum Therapeutics is a promising player in the field of biopharmaceuticals.
Fulcrum Therapeutics Inc's ticker is FULC
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachusetts
There are 51-200 employees working at Fulcrum Therapeutics Inc
It is fulcrumtx.com
Fulcrum Therapeutics Inc is in the Healthcare sector
Fulcrum Therapeutics Inc is in the Biotechnology industry
The following five companies are Fulcrum Therapeutics Inc's industry peers: